ArticleOphthalmology and therapy2023
Artificial Intelligence-Based Quantification of Central Macular Fluid Volume and VA Prediction for Diabetic Macular Edema Using OCT Images.
Article in Ophthalmology and therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project.The British journal of ophthalmology · 2026Article
- AI-based prediction of best-corrected visual acuity in patients with multiple retinal diseases using multimodal medical imaging.The British journal of ophthalmology · 2026Article
- Artificial Intelligence in Diabetic Retinopathy and Diabetic Macular Edema: A Narrative Review.Bioengineering (Basel, Switzerland) · 2025Review
- Artificial intelligence for early detection of diabetes mellitus complications via retinal imaging.Journal of diabetes and metabolic disorders · 2025Review
- Differences in Artificial Intelligence-Based Macular Fluid Parameters Between Clinical Stages of Diabetic Macular Edema and Their Relationship with Visual Acuity.Journal of clinical medicine · 2025Article
- Artificial intelligence in proliferative diabetic retinopathy: advancing diagnosis, precision surgery, and anti-VEGF therapy optimization.Frontiers in medicine · 2025Review
- Ocular Disease Detection with Deep Learning (Fine-Grained Image Categorization) Applied to Ocular B-Scan Ultrasound Images.Ophthalmology and therapy · 2024Article
- Novel artificial intelligence algorithms for diabetic retinopathy and diabetic macular edema.Eye and vision (London, England) · 2024Review
- Artificial Intelligence Applications in Diabetic Retinopathy: What We Have Now and What to Expect in the Future.Endocrinology and metabolism (Seoul, Korea) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionWe studied the correlation of central macular fluid volume (CMFV) and central subfield thickness (CST) with best-corrected visual acuity (BCVA) in treatment-naïve eyes with diabetic macular edema (DME) 1 month after anti-vascular endothelial growth factor (VEGF) therapy.
methodsThis retrospective cohort study investigated eyes that received anti-VEGF therapy. All participants underwent comprehensive examinations and optical coherence tomography (OCT) volume scans at baseline (M0) and 1 month after the first treatment (M1). Two deep learning models were separately developed to automatically measure the CMFV and the CST. Correlations were analyzed between the CMFV and the logMAR BCVA at M0 and logMAR BCVA at M1. The area under the receiver operating characteristic curve (AUROC) of CMFV and CST for predicting eyes with BCVA [Formula: see text] 20/40 at M1 was analyzed.
resultsThis study included 156 DME eyes from 89 patients. The median CMFV decreased from 0.272 (0.061-0.568) at M0 to 0.096 (0.018-0.307) mm
conclusionsAnti-VEGF therapy is an effective treatment for DME. Automated measured CMFV is a more accurate prognostic factor than CST for the initial anti-VEGF treatment outcome of DME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.